{"component": "clause", "props": {"groups": [{"size": 1, "snippet_links": [{"key": "license-in", "type": "definition", "offset": [4, 14]}, {"key": "section-521", "type": "clause", "offset": [15, 28]}, {"key": "rights-to-develop", "type": "clause", "offset": [45, 62]}, {"key": "corresponding-products", "type": "definition", "offset": [105, 127]}, {"key": "in-the-field", "type": "clause", "offset": [129, 141]}, {"key": "right-to-develop", "type": "clause", "offset": [202, 218]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [352, 385]}, {"key": "offer-for-sale", "type": "definition", "offset": [447, 461]}, {"key": "third-party", "type": "clause", "offset": [647, 658]}, {"key": "notwithstanding-the", "type": "definition", "offset": [691, 710]}, {"key": "during-the-term-of-the-agreement", "type": "clause", "offset": [718, 750]}, {"key": "right-to-conduct", "type": "clause", "offset": [772, 788]}, {"key": "clinical-research", "type": "clause", "offset": [793, 810]}, {"key": "any-e", "type": "clause", "offset": [816, 821]}], "snippet": "The license in Section 5.2.1 grants to Roche rights to develop and commercialize Licensed Compounds (and corresponding Products) in the Field. Roche agrees that such license does not grant to Roche any right to develop and/or commercialize any Compounds other than Licensed Compounds (and corresponding Products) in the Field, and further agrees that, during the term of this Agreement, Roche will not develop, make, have made, use, import, sell, offer for sale or otherwise commercialize, any Compounds other than Licensed Compounds (and corresponding Products) for use in the Field, and will not authorize, facilitate or assist any Affiliate or Third Party to conduct any such activities. Notwithstanding the above, during the term of the Agreement Roche shall have the right to conduct pre-clinical research with any E Compounds (except those that are then Maxygen Compounds) to assess which such E Compounds Roche wishes to select as Licensed Compounds.", "samples": [{"hash": "iU1Jqs2VcFp", "uri": "/contracts/iU1Jqs2VcFp#licensed-compounds", "label": "Co Development and Commercialization Agreement (Maxygen Inc)", "score": 21.0, "published": true}], "hash": "9d95ffe46aafa6fb90e292ac29d8e87b", "id": 10}, {"size": 3, "snippet_links": [{"key": "the-development-plan", "type": "clause", "offset": [0, 20]}, {"key": "primary-compound", "type": "definition", "offset": [29, 45]}, {"key": "schedule-1", "type": "definition", "offset": [68, 78]}, {"key": "licensed-compound", "type": "definition", "offset": [102, 119]}, {"key": "following-the", "type": "definition", "offset": [130, 143]}, {"key": "by-roche", "type": "clause", "offset": [153, 161]}, {"key": "collaboration-compound", "type": "definition", "offset": [234, 256]}, {"key": "the-parties-shall", "type": "clause", "offset": [258, 275]}, {"key": "cost-and-expense", "type": "clause", "offset": [464, 480]}, {"key": "obtaining-regulatory-approval", "type": "clause", "offset": [511, 540]}, {"key": "roche-territory", "type": "definition", "offset": [548, 563]}, {"key": "from-time-to-time", "type": "clause", "offset": [602, 619]}, {"key": "in-accordance-with", "type": "definition", "offset": [620, 638]}, {"key": "article-8", "type": "definition", "offset": [639, 648]}], "snippet": "The Development Plan for the Primary Compound is attached hereto as Schedule 1. For a given Potential Licensed Compound, promptly following the exercise by Roche of its Option designated such Potential Licensed Compound as a Licensed Collaboration Compound, the Parties shall, through JDMC, develop and adopt a Development Plan for such Licensed Collaboration Compound. Each Development Plan shall specify, among other things, that Roche shall conduct, at its own cost and expense, all activities in support of obtaining Regulatory Approval in the Roche Territory. Such Development Plan may be amended from time to time in accordance with Article 8.", "samples": [{"hash": "9E76KYgdKl0", "uri": "/contracts/9E76KYgdKl0#licensed-compounds", "label": "Collaboration Agreement (Pharmasset Inc)", "score": 21.8925393566, "published": true}, {"hash": "gsq0l3y6yey", "uri": "/contracts/gsq0l3y6yey#licensed-compounds", "label": "Collaboration Agreement (Pharmasset Inc)", "score": 21.0, "published": true}, {"hash": "8htVJLpfoPI", "uri": "/contracts/8htVJLpfoPI#licensed-compounds", "label": "Collaboration Agreement (Pharmasset Inc)", "score": 21.0, "published": true}], "hash": "6e19ddeabdf650e16cf2ba23147f8250", "id": 4}, {"size": 2, "snippet_links": [{"key": "period-of", "type": "definition", "offset": [6, 15]}, {"key": "selection-of", "type": "clause", "offset": [28, 40]}, {"key": "candidate-compound", "type": "definition", "offset": [43, 61]}, {"key": "right-to-conduct", "type": "clause", "offset": [85, 101]}, {"key": "development-and-evaluation", "type": "clause", "offset": [129, 155]}, {"key": "clinical-candidate", "type": "definition", "offset": [188, 206]}, {"key": "to-determine", "type": "definition", "offset": [212, 224]}, {"key": "sole-discretion", "type": "clause", "offset": [232, 247]}, {"key": "in-accordance-with-the-provisions-of-this-agreement", "type": "definition", "offset": [317, 368]}, {"key": "at-any-time", "type": "clause", "offset": [374, 385]}, {"key": "notice-thereof", "type": "clause", "offset": [549, 563]}, {"key": "all-purposes", "type": "definition", "offset": [641, 653]}, {"key": "research-compound", "type": "definition", "offset": [718, 735]}, {"key": "compound-criteria", "type": "definition", "offset": [781, 798]}, {"key": "research-program-term", "type": "clause", "offset": [927, 948]}, {"key": "pursuant-to", "type": "definition", "offset": [1085, 1096]}, {"key": "section-44", "type": "clause", "offset": [1102, 1113]}], "snippet": "For a period of [***] after selection of a Candidate Compound, Sankyo shall have the right to conduct more extensive preclinical development and evaluation of such Candidate Compound as a clinical candidate, and to determine in its sole discretion whether such Candidate Compound should be deemed a Licensed Compound in accordance with the provisions of this Agreement. If, at any time within such [***] period, Sankyo determines in its sole discretion that such Candidate Compound should be deemed a Licensed Compound, Sankyo shall provide written notice thereof to MTI. Thereafter, such Candidate Compound shall be a Licensed Compound for all purposes under this Agreement. Licensed Compounds shall also include any Research Compound that Sankyo determines meets the Recommended Compound Criteria, Recommended Compound and/or Candidate Compound which Sankyo may further develop following the termination or expiration of the Research Program Term in accordance with Sections 6.1.1, 14.2 and 14.3 and which Sankyo may determine, in its sole discretion, to deem as a Licensed Compound pursuant to this Section 4.4.", "samples": [{"hash": "8TdbGCZYN6r", "uri": "/contracts/8TdbGCZYN6r#licensed-compounds", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "1Tf64n1GC8B", "uri": "/contracts/1Tf64n1GC8B#licensed-compounds", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}], "hash": "fd6b846bc305939fb4890f72c382ea44", "id": 5}, {"size": 2, "snippet_links": [{"key": "licensed-compound", "type": "definition", "offset": [13, 30]}, {"key": "option-to", "type": "clause", "offset": [59, 68]}, {"key": "at-any-time", "type": "clause", "offset": [92, 103]}, {"key": "option-term", "type": "clause", "offset": [143, 154]}, {"key": "the-license", "type": "definition", "offset": [175, 186]}, {"key": "section-52", "type": "clause", "offset": [201, 212]}, {"key": "with-respect-to", "type": "clause", "offset": [213, 228]}, {"key": "provision-of-the", "type": "clause", "offset": [435, 451]}, {"key": "receipt-of", "type": "clause", "offset": [607, 617]}, {"key": "declaration-date", "type": "definition", "offset": [651, 667]}, {"key": "subject-of", "type": "clause", "offset": [707, 717]}, {"key": "subject-to-the", "type": "definition", "offset": [786, 800]}, {"key": "third-party", "type": "clause", "offset": [927, 938]}, {"key": "all-necessary-documents", "type": "clause", "offset": [1016, 1039]}, {"key": "pursuant-to", "type": "definition", "offset": [1067, 1078]}, {"key": "article-5", "type": "clause", "offset": [1084, 1093]}], "snippet": "5.1 CHIRON'S LICENSED COMPOUND DECLARATION AND EXERCISE OF OPTION TO LICENSED COMPOUND.\n(a) At any time within the OVLS Evaluation License and Option Term., Chiron may secure the License referenced in Section 5.2 with respect to any or all compounds contained within a Optioned Validated Lead Structure Series by notifying Phytera of Chiron's interest in obtaining the License referenced in Section 5.2 (the \"LC DECLARATION\") Chiron's provision of the LC Declaration to Phytera shall constitute Chiron's exercise of its option to the Optioned Validated Lead Structure Series in question, and upon Phytera's receipt of Chiron's LC Declaration (the \"LC DECLARATION DATE\"), any and all compounds which are the subject of Chiron's LC Declaration will be deemed to be a Licensed Compound(s) subject to the License referenced in Section 5.2.\n(b) Phytera shall execute (and shall ensure that any of its employees execute and that any third party involved in the discovery or invention over whom they have control executes) all necessary documents to perfect Chiron's rights pursuant to this Article 5.", "samples": [{"hash": "j9clKJT7FQy", "uri": "/contracts/j9clKJT7FQy#licensed-compounds", "label": "Collaboration Agreement (Phytera Inc)", "score": 18.0, "published": true}, {"hash": "hvlk2dAF11v", "uri": "/contracts/hvlk2dAF11v#licensed-compounds", "label": "Collaboration Agreement (Phytera Inc)", "score": 18.0, "published": true}], "hash": "550d306e949067d6d216078b60872e26", "id": 6}, {"size": 2, "snippet_links": [{"key": "generated-data", "type": "definition", "offset": [93, 107]}, {"key": "licensed-know", "type": "definition", "offset": [133, 146]}, {"key": "other-data", "type": "definition", "offset": [154, 164]}, {"key": "to-licensee", "type": "definition", "offset": [204, 215]}], "snippet": "Schedule 1.60 lists those compounds which Sanofi Developed in its [***] for which Sanofi has generated data which is included in the Licensed Know-How or Other Data. Sanofi does not represent and warrant to Licensee that Schedule 1.60 lists all compounds which Sanofi Developed in its [***].", "samples": [{"hash": "lqt1MmDpTdk", "uri": "/contracts/lqt1MmDpTdk#licensed-compounds", "label": "License Agreement (Khosla Ventures Acquisition Co.)", "score": 32.8001368925, "published": true}], "hash": "46d62c731251098563dbd08e9156b736", "id": 7}, {"size": 5, "snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [0, 14]}, {"key": "with-respect-to", "type": "clause", "offset": [33, 48]}, {"key": "the-development", "type": "clause", "offset": [49, 64]}], "snippet": "This Agreement will be exclusive with respect to the Development, Manufacture, and Commercialization of [*] that are intended to [*] as described below [*].", "samples": [{"hash": "jC7NerxKQHp", "uri": "/contracts/jC7NerxKQHp#licensed-compounds", "label": "Collaboration Agreement (Exelixis, Inc.)", "score": 27.5872689938, "published": true}, {"hash": "fxkopCP0FKV", "uri": "/contracts/fxkopCP0FKV#licensed-compounds", "label": "Collaboration Agreement (Exelixis Inc)", "score": 22.5879534565, "published": true}], "hash": "308ab716f09dc95283a3ae11c3423782", "id": 1}, {"size": 3, "snippet_links": [{"key": "pay-to", "type": "definition", "offset": [12, 18]}, {"key": "first-occurrence", "type": "clause", "offset": [107, 123]}, {"key": "licensed-compound", "type": "definition", "offset": [152, 169]}], "snippet": "Roche shall pay to Pharmasset the following nonrefundable payments (shown in [***] of US dollars) upon the first occurrence of the following events for Licensed Compound: [***] [***] [***]", "samples": [{"hash": "9E76KYgdKl0", "uri": "/contracts/9E76KYgdKl0#licensed-compounds", "label": "Collaboration Agreement (Pharmasset Inc)", "score": 21.8925393566, "published": true}, {"hash": "gsq0l3y6yey", "uri": "/contracts/gsq0l3y6yey#licensed-compounds", "label": "Collaboration Agreement (Pharmasset Inc)", "score": 21.0, "published": true}, {"hash": "8htVJLpfoPI", "uri": "/contracts/8htVJLpfoPI#licensed-compounds", "label": "Collaboration Agreement (Pharmasset Inc)", "score": 21.0, "published": true}], "hash": "8e0b68b9b29f20372f9829ed4b3c9299", "id": 2}, {"size": 3, "snippet_links": [{"key": "active-compound", "type": "definition", "offset": [5, 20]}, {"key": "the-criteria", "type": "clause", "offset": [33, 45]}, {"key": "satisfaction-of", "type": "clause", "offset": [78, 93]}, {"key": "research-committee", "type": "definition", "offset": [98, 116]}, {"key": "right-to-select", "type": "clause", "offset": [196, 211]}, {"key": "glp-toxicology-study", "type": "definition", "offset": [266, 286]}, {"key": "development-and-commercialization", "type": "clause", "offset": [299, 332]}, {"key": "the-license-agreement", "type": "clause", "offset": [339, 360]}, {"key": "notice-to", "type": "definition", "offset": [402, 411]}, {"key": "licensed-compound", "type": "definition", "offset": [477, 494]}, {"key": "covered-by", "type": "definition", "offset": [508, 518]}, {"key": "terms-of-the-license", "type": "clause", "offset": [523, 543]}], "snippet": "Each Active Compound which meets the criteria set forth in Exhibit 2.3 to the satisfaction of the Research Committee may be recommended by the Research Committee to Dainippon which shall have the right to select from those so recommended the Active Compound for the GLP Toxicology Study and further development and commercialization under the License Agreement. Such selection shall be made by written notice to RiboGene. Each Active Compound so selected shall be designated a Licensed Compound and shall be covered by the terms of the License Agreement.", "samples": [{"hash": "hCx7tj4ybWw", "uri": "/contracts/hCx7tj4ybWw#licensed-compounds", "label": "Research Agreement (Ribogene Inc / Ca/)", "score": 18.0, "published": true}, {"hash": "baT0Ish6E5J", "uri": "/contracts/baT0Ish6E5J#licensed-compounds", "label": "Research Agreement (Ribogene Inc / Ca/)", "score": 18.0, "published": true}, {"hash": "8UnByd8C4Sc", "uri": "/contracts/8UnByd8C4Sc#licensed-compounds", "label": "Research Agreement (Ribogene Inc / Ca/)", "score": 18.0, "published": true}], "hash": "e5044f3efc08efa018810ad266581d59", "id": 3}, {"size": 1, "snippet_links": [{"key": "that-\u2587", "type": "clause", "offset": [41, 47]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [97, 121]}, {"key": "the-definition-of", "type": "definition", "offset": [133, 150]}, {"key": "licensed-compound", "type": "definition", "offset": [152, 169]}], "snippet": "\u2587\u2587\u2587\u2587 has disclosed to EQRx all compounds that \u2587\u2587\u2587\u2587 or any of its Affiliates owns or in-licenses, as of the Effective Date, that meet the definition of \u201cLicensed Compound\u201d hereunder.", "samples": [{"hash": "h2o73Ukdm5W", "uri": "/contracts/h2o73Ukdm5W#licensed-compounds", "label": "Exclusive License Agreement (CM Life Sciences III Inc.)", "score": 32.8247775496, "published": true}], "hash": "b779b638355efbb1b5263e417c7235bf", "id": 8}, {"size": 1, "snippet_links": [{"key": "the-agreement", "type": "clause", "offset": [16, 29]}, {"key": "amended-and-restated", "type": "definition", "offset": [40, 60]}], "snippet": "Section 1.29 of the Agreement is hereby amended and restated as follows:", "samples": [{"hash": "hBNeAYhBJ1h", "uri": "/contracts/hBNeAYhBJ1h#licensed-compounds", "label": "Collaboration and License Agreement (Cv Therapeutics Inc)", "score": 21.0, "published": true}], "hash": "c1e5de36fc8df056cd54a9412494ea20", "id": 9}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhtsaWNlbnNlZC1jb21wb3VuZHMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"size": 25, "parents": [["exclusivity", "Exclusivity"], ["payments-to-pharmasset", "Payments to Pharmasset"], ["development-event-fees", "Development Event Fees"], ["research-and-development", "Research and Development"], ["definitions", "DEFINITIONS"]], "title": "Licensed Compounds", "children": [["subsequent-to-commercialization", "Subsequent to Commercialization"], ["prior-to-commercialization", "Prior to Commercialization"], ["licensed-compound-and-product-license", "LICENSED COMPOUND AND PRODUCT LICENSE"], ["passed-compounds", "Passed Compounds"], ["addition-of-licensed-compounds", "Addition of Licensed Compounds"]], "id": "licensed-compounds", "related": [["licensed-products", "Licensed Products", "Licensed Products"], ["licensed-product", "Licensed Product", "Licensed Product"], ["commercialization", "Commercialization", "Commercialization"], ["licensed-technology", "Licensed Technology", "Licensed Technology"], ["commercialization-license", "Commercialization License", "Commercialization License"]], "related_snippets": [], "updated": "2025-07-07T12:37:40+00:00", "also_ask": ["What are the minimum definitional elements required to clearly identify 'Licensed Compounds'?", "How can the scope of 'Licensed Compounds' be strategically expanded or narrowed during negotiations?", "What are the key risks if the definition of 'Licensed Compounds' is ambiguous or overly broad?", "How does this clause compare to industry standards or similar agreements regarding compound coverage?", "What factors most influence a court\u2019s interpretation and enforceability of the 'Licensed Compounds' definition?"], "drafting_tip": "Define the chemical structure and variants of Licensed Compounds to avoid ambiguity; specify inclusion or exclusion of derivatives to clarify rights; reference authoritative sources to ensure enforceability.", "explanation": "The 'Licensed Compounds' clause defines the specific chemical compounds or products that are covered under a licensing agreement. It typically lists or describes the compounds by name, structure, or class, and may include criteria for future compounds that fall within the licensed scope. This clause ensures both parties are clear on which substances are subject to the license, thereby preventing disputes over the use, development, or commercialization of related compounds."}, "json": true, "cursor": ""}}